258 related articles for article (PubMed ID: 10392633)
1. mdm-2 expression correlates with wild-type p53 status in esophageal adenocarcinoma.
Soslow RA; Altorki NK; Yang G; Xie D; Yang CS
Mod Pathol; 1999 Jun; 12(6):580-6. PubMed ID: 10392633
[TBL] [Abstract][Full Text] [Related]
2. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
3. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
4. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus.
Schneider PM; Stoeltzing O; Roth JA; Hoelscher AH; Wegerer S; Mizumoto S; Becker K; Dittler HJ; Fink U; Siewert JR
Clin Cancer Res; 2000 Aug; 6(8):3153-8. PubMed ID: 10955797
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical and molecular evaluation of the mdm-2 gene product in bronchogenic carcinoma.
Gorgoulis VG; Rassidakis GZ; Karameris AM; Papastamatiou H; Trigidou R; Veslemes M; Rassidakis AN; Kittas C
Mod Pathol; 1996 May; 9(5):544-54. PubMed ID: 8733770
[TBL] [Abstract][Full Text] [Related]
6. Nuclear accumulation of beta-catenin is a common and early event during neoplastic progression of Barrett esophagus.
Bian YS; Osterheld MC; Bosman FT; Fontolliet C; Benhattar J
Am J Clin Pathol; 2000 Oct; 114(4):583-90. PubMed ID: 11026105
[TBL] [Abstract][Full Text] [Related]
7. Immunohistological study of cell cycle-related factors, oncogene expression, and cell proliferation in adenocarcinoma developed in Barrett's esophagus.
Fujii T; Nakagawa S; Hanzawa M; Sueyoshi S; Fujita H; Shirouzu K; Yamana H
Oncol Rep; 2003; 10(2):427-31. PubMed ID: 12579284
[TBL] [Abstract][Full Text] [Related]
8. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma.
Oda Y; Sakamoto A; Satio T; Kawauchi S; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2000 Sep; 13(9):994-1004. PubMed ID: 11007040
[TBL] [Abstract][Full Text] [Related]
9. Intestinal differentiation and p53 gene alterations in Barrett's esophagus and esophageal adenocarcinoma.
Moore JH; Lesser EJ; Erdody DH; Natale RB; Orringer MB; Beer DG
Int J Cancer; 1994 Feb; 56(4):487-93. PubMed ID: 7906678
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneous distribution of P53 immunoreactivity in human lung adenocarcinoma correlates with MDM2 protein expression, rather than with P53 gene mutation.
Koga T; Hashimoto S; Sugio K; Yoshino I; Nakagawa K; Yonemitsu Y; Sugimachi K; Sueishi K
Int J Cancer; 2001 Jul; 95(4):232-9. PubMed ID: 11400116
[TBL] [Abstract][Full Text] [Related]
11. p53 mutation without allelic loss and absence of mdm-2 amplification in a transplantable hamster pancreatic ductal adenocarcinoma and derived cell lines but not primary ductal adenocarcinomas in hamsters.
Okita S; Tsutsumi M; Onji M; Konishi Y
Mol Carcinog; 1995 Aug; 13(4):266-71. PubMed ID: 7646765
[TBL] [Abstract][Full Text] [Related]
12. Melanoma-associated antigens in esophageal adenocarcinoma: identification of novel MAGE-A10 splice variants.
Lin J; Lin L; Thomas DG; Greenson JK; Giordano TJ; Robinson GS; Barve RA; Weishaar FA; Taylor JM; Orringer MB; Beer DG
Clin Cancer Res; 2004 Sep; 10(17):5708-16. PubMed ID: 15355897
[TBL] [Abstract][Full Text] [Related]
13. p53 mutation, murine double minute 2 amplification, and human papillomavirus infection are frequently involved but not associated with each other in esophageal squamous cell carcinoma.
Shibagaki I; Tanaka H; Shimada Y; Wagata T; Ikenaga M; Imamura M; Ishizaki K
Clin Cancer Res; 1995 Jul; 1(7):769-73. PubMed ID: 9816044
[TBL] [Abstract][Full Text] [Related]
14. P53 expression in Reed-Sternberg cells does not correlate with gene mutations in Hodgkin's disease.
Elenitoba-Johnson KS; Medeiros LJ; Khorsand J; King TC
Am J Clin Pathol; 1996 Dec; 106(6):728-38. PubMed ID: 8980348
[TBL] [Abstract][Full Text] [Related]
15. Human papillomavirus infection in Egyptian esophageal carcinoma: correlation with p53, p21, mdm2, C-erbB2 and impact on survival.
Bahnassy AA; Zekri AR; Abdallah S; El-Shehaby AM; Sherif GM
Pathol Int; 2005 Feb; 55(2):53-62. PubMed ID: 15693850
[TBL] [Abstract][Full Text] [Related]
16. Malignant degeneration of Barrett's esophagus: the role of the Ki-67 proliferation fraction, expression of E-cadherin and p53.
Feith M; Stein HJ; Mueller J; Siewert JR
Dis Esophagus; 2004; 17(4):322-7. PubMed ID: 15569371
[TBL] [Abstract][Full Text] [Related]
17. Abnormal expression of MDM2 in prostate carcinoma.
Leite KR; Franco MF; Srougi M; Nesrallah LJ; Nesrallah A; Bevilacqua RG; Darini E; Carvalho CM; Meirelles MI; Santana I; Camara-Lopes LH
Mod Pathol; 2001 May; 14(5):428-36. PubMed ID: 11353053
[TBL] [Abstract][Full Text] [Related]
18. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods.
Lu ML; Wikman F; Orntoft TF; Charytonowicz E; Rabbani F; Zhang Z; Dalbagni G; Pohar KS; Yu G; Cordon-Cardo C
Clin Cancer Res; 2002 Jan; 8(1):171-9. PubMed ID: 11801555
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical detection of p53 in melanomas with rare p53 gene mutations is associated with mdm-2 overexpression.
Poremba C; Yandell DW; Metze D; Kamanabrou D; Böcker W; Dockhorn-Dworniczak B
Oncol Res; 1995; 7(7-8):331-9. PubMed ID: 8747596
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the p53 and MDM-2 gene in acute myeloid leukemia.
Seliger B; Papadileris S; Vogel D; Hess G; Brendel C; Störkel S; Ortel J; Kolbe K; Huber C; Huhn D; Neubauer A
Eur J Haematol; 1996 Sep; 57(3):230-40. PubMed ID: 8898928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]